Literature DB >> 20948440

Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Lynn T Dengel1, Allison G Norrod, Briana L Gregory, Eleanor Clancy-Thompson, Marie D Burdick, Robert M Strieter, Craig L Slingluff, David W Mullins.   

Abstract

Immune-mediated cancer regression requires tumor infiltration by antigen-specific effector T cells, but lymphocytes are commonly sparse in melanoma metastases. Activated T cells express CXCR3, whose cognate chemokines are CXCL9/MIG, CXCL10/IP-10, and CXCL11/I-TAC. Little is known about expression of these chemokines in lymph node (LN) metastases of melanoma. We evaluated whether metastatic melanoma induces these CXCR3-cognate chemokines in human LN-derived tissues. In addition, as these chemokines can be induced by interferon (IFN), we evaluated whether type I or II IFNs (IFN-α or IFN-γ, respectively) can modulate chemokine expression in an in vitro model of the human tumor microenvironment. Production of CXCL9-11 by melanoma-infiltrated nodes (MIN) was no different than tumor-free nodes; both produced less chemokine than activated LN (sentinel immunized nodes, SIN). These data suggest that melanoma infiltration into LN neither induces nor reduces CXCL9-11. Stimulation with IFN-α or IFN-γ increased production of CXCL10-11 from MIN, but not tumor-free node or SIN. IFN-γ also increased production of CXCL9 in MIN. In IFN-treated SIN, CD14+ cells were the primary source of CXCL9-11, whereas melanoma cells were the source of chemokine in MIN. Melanoma cells in MIN express IFN receptors. Consistent with these observations, multiple human melanoma lines expressed IFN receptors and produced CXCL9-11 in response to IFN treatment. Thus, melanoma infiltration of LN is insufficient to induce the production of CXCL9-11, but melanoma may be a significant source of IFN-induced chemokines. Collectively, these data suggest that IFN-α or IFN-γ may act in the tumor microenvironment to increase the chemotactic gradient for CXCR3+ T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20948440      PMCID: PMC3110268          DOI: 10.1097/CJI.0b013e3181fb045d

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  45 in total

1.  Improved superoxide-generating ability by interferon gamma due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene.

Authors:  F Ishibashi; T Mizukami; S Kanegasaki; L Motoda; R Kakinuma; F Endo; H Nunoi
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

2.  Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma.

Authors:  M Kunz; A Toksoy; M Goebeler; E Engelhardt; E Bröcker; R Gillitzer
Journal:  J Pathol       Date:  1999-12       Impact factor: 7.996

3.  Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Authors:  C L Slingluff; G Yamshchikov; P Neese; H Galavotti; S Eastham; V H Engelhard; D Kittlesen; D Deacon; S Hibbitts; W W Grosh; G Petroni; R Cohen; C Wiernasz; J W Patterson; B P Conway; W G Ross
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

4.  Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states.

Authors:  M A Cox; C H Jenh; W Gonsiorek; J Fine; S K Narula; P J Zavodny; R W Hipkin
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

5.  Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.

Authors:  M Meyer; P J Hensbergen; E M van der Raaij-Helmer; G Brandacher; R Margreiter; C Heufler; F Koch; S Narumi; E R Werner; R Colvin; A D Luster; C P Tensen; G Werner-Felmayer
Journal:  Eur J Immunol       Date:  2001-08       Impact factor: 5.532

6.  IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.

Authors:  Elisabetta Padovan; Giulio C Spagnoli; Maria Ferrantini; Michael Heberer
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

7.  CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.

Authors:  Irene M Mullins; Craig L Slingluff; Jae K Lee; Courtney F Garbee; Jianfen Shu; Sara G Anderson; Melanie E Mayer; William A Knaus; David W Mullins
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

Authors:  G V Yamshchikov; D L Barnd; S Eastham; H Galavotti; J W Patterson; D H Deacon; D Teates; P Neese; W W Grosh; G Petroni; V H Engelhard; C L Slingluff
Journal:  Int J Cancer       Date:  2001-06-01       Impact factor: 7.396

9.  Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells.

Authors:  J Yamamoto; Y Adachi; Y Onoue; Y S Adachi; Y Okabe; T Itazawa; M Toyoda; T Seki; M Morohashi; K Matsushima; T Miyawaki
Journal:  J Leukoc Biol       Date:  2000-10       Impact factor: 4.962

10.  Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment.

Authors:  M J Janatpour; S Hudak; M Sathe; J D Sedgwick; L M McEvoy
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

View more
  36 in total

1.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

2.  The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10.

Authors:  Keiji Tanese; Elizabeth A Grimm; Suhendan Ekmekcioglu
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

Review 3.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

4.  Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

Authors:  Jared Klarquist; Kristen Tobin; Peyman Farhangi Oskuei; Steven W Henning; Manuel F Fernandez; Emilia R Dellacecca; Flor C Navarro; Jonathan M Eby; Shilpak Chatterjee; Shikhar Mehrotra; Joseph I Clark; I Caroline Le Poole
Journal:  Cancer Res       Date:  2016-09-12       Impact factor: 12.701

Review 5.  Crosstalk between type I and II interferons in regulation of myeloid cell responses during bacterial infection.

Authors:  William J Crisler; Laurel L Lenz
Journal:  Curr Opin Immunol       Date:  2018-06-07       Impact factor: 7.486

6.  A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).

Authors:  Craig L Slingluff; Sandra Lee; Fengmin Zhao; Kimberly A Chianese-Bullock; Walter C Olson; Lisa H Butterfield; Theresa L Whiteside; Philip D Leming; John M Kirkwood
Journal:  Clin Cancer Res       Date:  2013-05-07       Impact factor: 12.531

7.  Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.

Authors:  Eleanor Clancy-Thompson; Thomas J Perekslis; Walburga Croteau; Matthew P Alexander; Tamer B Chabanet; Mary Jo Turk; Yina H Huang; David W Mullins
Journal:  Cancer Immunol Res       Date:  2015-06-05       Impact factor: 11.151

8.  TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Authors:  Ileana S Mauldin; Ena Wang; Donna H Deacon; Walter C Olson; Yongde Bao; Craig L Slingluff
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

Review 9.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

10.  Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Mark E Smolkin; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja V Galeassi; Kimberly A Chianese-Bullock; Lynn T Dengel; Francesco M Marincola; Gina R Petroni; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.